Slide 1

CONFIDENTIAL Michael Nagel, President and CEO

Slide 2

How Is New Technology Viewed? Gee Whiz has become So What?

Slide 3

The OLD Sales Model & Conversation Patien t Physician Gatekeeper The Story: Technology Features, Benefits, Advantages Hospital Sales Rep

Slide 4

A New Sales Model & Conversation Gatekeepers GP O IDN GOVT Hospital Outpatient Facility Long Term Care Facility The Story: Cost-benefit, Economic Feasibility, Risk Sharing, Added Value Patien t Physician Sales Rep Corp Accts

Slide 5

Slide 6

Elemental Silver Imbedded in the dressing are wireless microcell batteries Elemental Zinc In the presence of a conductive fluid (i.e. saline, hydrogel, wound exudate) batteries are activated and generate microcurrents at the dressing surface Procellera Technology is the first of its kind microcurrent generating antimicrobial wound dressing

Slide 7

Todays Environment More capital investment required More time less room for errors More evidence required More decision makers Less investment capital available calls for a different approach

Slide 8

What Builds Value For Stakeholders? Potential market size Clinical value Patents Margins Share of market AND economic viability of technology

Slide 9

Funding Infrastructure Technology Evidence Strategic Plans Tactical Execution Strategic Plans Tactical Execution Top / Bottom Line Growth Key hires and abilities needed at this stage Todays Strategic Outlook Studies must aim at demonstrating BOTH clinical and economic value Partnerships may be KEY to future technologies

Slide 10

10 Scientific & Clinical Evidence Inspired by the body. Powered by electricity. Energized by results.

Slide 11

Research Collaborators 11

Slide 12

Broad Scientific and Clinical Interest GROWING BODY OF EVIDENCE 7 Publications & 49 Peer Reviewed Abstracts

Slide 13

NOTE: Multicenter retrospective study; N=38 (SOC n=20, Procellera n=18) Acute & chronic, partial & full- thickness wounds Whitcomb E, Monroe N, Hope-Higman J, Campbell P. Demonstration of a Microcurrent-Generating Wound Care Device for Wound Healing within a Rehabilitation Center Patient Population. Journal of the American College of Clinical Wound Specialists 2013; 4(2):32-39. Day 0 Week 3 13 Reduced Healing Time RETROSPECTIVE CLINICAL STUDY

Slide 14

St. Lukes Medical Center Total Knee Arthroplasty, Retrospective; N=100 Findings: Reduced LOS, readmission and infection rates vs. published literature Clinical & Cost Efficacy Studies with Procellera Reduced LOS 3.5 Days 2.4 Days Reduced Infection & Readmission Rates Tribal Healthcare Facility Acute /chronic wounds, retrospective; N=18 Findings: Reduced cost/cm2 to heal vs. skin substitutes, NPWT; 47% reduced time to heal Chow et al, Orthopedics 2014. Manuscript in submission.Yamada et al, SAWC 2014

Slide 15

Clinical & Cost Efficacy of Procellera + NPWT Acute surgical wounds, prospective, N=30 Interim Findings: 22% cost savings in NPWT costs and 33% cost savings in narcotic analgesic costs, vs. NPWT alone Reduced healing times and reduced dressing changes Reduced CostImproved Closure Rates vs. NPWT alone Barki, Das, Schlanger et al. Bioelectric Dressing Reduces Cost of Care for Ipatients with Acute Surgical Wounds Treated with NPWT. In: 7 th Annual Translational to Clinical Regenerative Medicine Wound Care Conference, Columbus, OH. March 2014. # of Participants

Slide 16

August 1, 2014 GPO Contract Status

Slide 17

New Model For Winning Teams Diverse strengths and backgrounds no duplicity Wide use of consultants best in class Engaged employees that connect to the mission Flexibility and speed to market

Slide 18

New Model for Device Companies Companies must operate leaner Substance over fluff Studies must be well designed and strategy carefully thought out Clear line of sight to core competencies Rethink traditional sales models Service (value-add) takes on new importance Partnership considerations